Dongkook Pharmaceutical Records Highest Quarterly Performance...Smooth Sailing Expected This Year

[Asia Economy Reporter Park Jihwan] Ebest Investment & Securities evaluated that Dongkook Pharmaceutical achieved its highest quarterly performance in the fourth quarter of last year and expects steady performance this year as well. The investment opinion 'Maintain' and the target stock price of 110,000 KRW were maintained.

Researcher Jeong Hongsik of Ebest Investment & Securities explained, "The fourth quarter results last year showed sales of 127.7 billion KRW and operating profit of 21 billion KRW, increasing by 25.6% and 63.9% respectively compared to the previous year, and net profit also rose by 17.9% to 16.6 billion KRW." This corresponds to the highest quarterly performance ever. In particular, it was analyzed as a record that surpassed the highest operating profit of 18.1 billion KRW achieved in the third quarter by 15.8% in just one quarter.

Researcher Jeong analyzed the background of this performance increase, saying, "Profitability improved based on the expansion of online and offline channels and strengthened competitiveness in home shopping within the healthcare business division, and the marketing expenses concentrated in the first half decreased in the fourth quarter."

Researcher Jeong forecasted, "The healthcare division grew by 48.1% year-on-year to 36.6 billion KRW," and added, "This year as well, the high-growth foundation growth trend is expected to be maintained based on the healthcare division."

This content was produced with the assistance of AI translation services.